# Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma

> **NCT07450508** · PHASE3 · COMPLETED · sponsor: **Cairo University** · enrollment: 88 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma Relapsed

## Interventions

- **COMBINATION_PRODUCT:** BEGEV (Bendamustine, Gemcitabine,Vinorelbine)
- **COMBINATION_PRODUCT:** GDP(Gemcitabine, Dexamethasone and Cisplatin)

## Key facts

- **NCT ID:** NCT07450508
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-30
- **Primary completion:** 2024-10-30
- **Final completion:** 2026-02-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450508, "Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07450508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*